19.2
Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators play a pivotal role in asthma management. They ease airway constriction by relaxing bronchial muscles.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors on bronchial smooth muscle cells. This induces muscle relaxation, facilitating the bronchial passages' dilation and relieving symptoms such as wheezing, shortness of breath, and chest tightness.
These agonists are categorized as short-acting β2-agonists or SABAs and long-acting β2-agonists or LABAs. SABAs, such as albuterol and terbutaline, provide immediate relief by promptly relaxing airway muscles during acute episodes.
Conversely, LABAs, such as salmeterol and formoterol, sustain bronchodilation and serve as preventive measures for chronic bronchial conditions.
These medications are often administered via metered-dose inhalers or nebulizers to ensure direct and rapid delivery to the respiratory tract.
Despite their benefits, β2-agonists may yield undesired systemic effects. The most common adverse effect is tremor, while potential side effects encompass tachycardia and cardiac dysrhythmia.
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these muscles, dilating the bronchial passages. This action helps alleviate common asthma symptoms such as wheezing, shortness of breath, and chest tightness.
β2-adrenoceptor agonists can be further categorized into short-acting β2-agonists (SABAs) and long-acting β2-agonists (LABAs). SABAs, including drugs like albuterol and terbutaline (Bricanyl), immediately relieve asthma symptoms. They quickly relax the airway muscles during acute episodes, making them essential for emergencies.
In contrast, LABAs, such as salmeterol (Severent) and formoterol (Symbicort), sustain bronchodilation over an extended period. They are typically used as preventive measures for chronic bronchial conditions, helping to maintain open airways and prevent asthma attacks from occurring.
These medications are often administered via metered-dose inhalers or nebulizers. These devices ensure direct and rapid medication delivery to the respiratory tract, maximizing their effectiveness while minimizing systemic exposure.
Despite their significant benefits in managing asthma, β2-agonists may also yield undesired systemic effects due to their stimulatory action on β2-adrenoceptors present in other parts of the body. The most common adverse effect is tremor, which results from stimulating β2-adrenoceptors in skeletal muscles. Other potential side effects include tachycardia (rapid heart rate) and cardiac dysrhythmias (irregular heart rhythms) resulting from β2-adrenoceptors stimulation in the heart. Patients must use these medications under medical supervision and promptly report any adverse effects.
Bronchodilators play a pivotal role in asthma management. They ease airway constriction by relaxing bronchial muscles.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors on bronchial smooth muscle cells. This induces muscle relaxation, facilitating the bronchial passages' dilation and relieving symptoms such as wheezing, shortness of breath, and chest tightness.
These agonists are categorized as short-acting β2-agonists or SABAs and long-acting β2-agonists or LABAs. SABAs, such as albuterol and terbutaline, provide immediate relief by promptly relaxing airway muscles during acute episodes.
Conversely, LABAs, such as salmeterol and formoterol, sustain bronchodilation and serve as preventive measures for chronic bronchial conditions.
These medications are often administered via metered-dose inhalers or nebulizers to ensure direct and rapid delivery to the respiratory tract.
Despite their benefits, β2-agonists may yield undesired systemic effects. The most common adverse effect is tremor, while potential side effects encompass tachycardia and cardiac dysrhythmia.
From Chapter 19:
Now Playing
19.2 : Antiasthma Drugs: β2-Adrenoceptor Agonists
Lower Respiratory Disorders
2.2K Views
19.1 : Asthma: Pathogenesis and Management
Lower Respiratory Disorders
1.6K Views
19.3 : Antiasthma Drugs: Methylxanthines
Lower Respiratory Disorders
2.1K Views
19.4 : Antiasthma Drugs: Leukotriene Modifiers
Lower Respiratory Disorders
2.3K Views
19.5 : Antiasthma Drugs: Muscarinic Receptor Antagonists
Lower Respiratory Disorders
2.3K Views
19.6 : Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Lower Respiratory Disorders
2.3K Views
19.7 : Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Lower Respiratory Disorders
2.6K Views
19.8 : COPD: Pathogenesis and Clinical Features
Lower Respiratory Disorders
2.4K Views
19.9 : COPD: Management Using Bronchodilators and Corticosteroids
Lower Respiratory Disorders
1.4K Views